# EDGAR Filing Document

**Accession Number:** 0001796356
**File Stem:** 0001193125-26-038199
**Filing Date:** 2026-2
**Character Count:** 16130
**Document Hash:** c3184d94ecae15b26676c20f25a3263c
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-038199.hdr.sgml**: 20260204

**ACCESSION NUMBER**: 0001193125-26-038199

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260204

**FILED AS OF DATE**: 20260204

**DATE AS OF CHANGE**: 20260204

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Column Group IV-A, LP
- **CENTRAL INDEX KEY:** 0001796353

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600229

**BUSINESS ADDRESS:**
- **STREET 1:** 1700 OWENS STREET, SUITE 500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
- **BUSINESS PHONE:** 415-865-2050

**MAIL ADDRESS:**
- **STREET 1:** 1700 OWENS STREET, SUITE 500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Column Group IV GP, LP
- **CENTRAL INDEX KEY:** 0001796356

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600230

**BUSINESS ADDRESS:**
- **STREET 1:** 1700 OWENS STREET, SUITE 500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
- **BUSINESS PHONE:** 415-865-2050

**MAIL ADDRESS:**
- **STREET 1:** 1700 OWENS STREET, SUITE 500
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94158
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Column Group Opportunity III GP, LP
- **CENTRAL INDEX KEY:** 0001932874

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600227

**BUSINESS ADDRESS:**
- **STREET 1:** 1 LETTERMAN DRIVE, BUILDING D
- **STREET 2:** SUITE DM-900
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94129
- **BUSINESS PHONE:** 415-865-2050

**MAIL ADDRESS:**
- **STREET 1:** 1 LETTERMAN DRIVE, BUILDING D
- **STREET 2:** SUITE DM-900
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94129
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Column Group Opportunity III, LP
- **CENTRAL INDEX KEY:** 0001931825

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600228

**BUSINESS ADDRESS:**
- **STREET 1:** 1 LETTERMAN DRIVE, BUILDING D
- **STREET 2:** SUITE DM-900
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94129
- **BUSINESS PHONE:** 415-865-2050

**MAIL ADDRESS:**
- **STREET 1:** 1 LETTERMAN DRIVE, BUILDING D
- **STREET 2:** SUITE DM-900
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94129
**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** TCG Opportunity III GP, LLC
- **CENTRAL INDEX KEY:** 0001932445

**ORGANIZATION NAME:**
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-43085
- **FILM NUMBER:** 26600226

**BUSINESS ADDRESS:**
- **STREET 1:** 1 LETTERMAN DRIVE, BUILDING D
- **STREET 2:** SUITE DM-900
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94129
- **BUSINESS PHONE:** 415-865-2050

**MAIL ADDRESS:**
- **STREET 1:** 1 LETTERMAN DRIVE, BUILDING D
- **STREET 2:** SUITE DM-900
- **CITY:** SAN FRANCISCO
- **STATE:** CA
- **ZIP:** 94129
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Eikon Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001861123
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 842807586
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030
- **BUSINESS PHONE:** 341-777-0566

**MAIL ADDRESS:**
- **STREET 1:** 230 HARRIET TUBMAN WAY
- **CITY:** MILLBRAE
- **STATE:** CA
- **ZIP:** 94030

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Column Group IV GP, LP<br><sub>(Last) (First) (Middle)</sub><br>1 LETTERMAN DRIVE<br>BUILDING D, SUITE DM-900<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94129<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Column Group IV-A, LP<br><sub>(Last) (First) (Middle)</sub><br>1 LETTERMAN DRIVE<br>BUILDING D, SUITE DM-900<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94129<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Column Group Opportunity III, LP<br><sub>(Last) (First) (Middle)</sub><br>1 LETTERMAN DRIVE<br>BUILDING D, SUITE DM-900<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94129<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Column Group Opportunity III GP, LP<br><sub>(Last) (First) (Middle)</sub><br>1 LETTERMAN DRIVE<br>BUILDING D, SUITE DM-900<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94129<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>TCG Opportunity III GP, LLC<br><sub>(Last) (First) (Middle)</sub><br>1 LETTERMAN DRIVE<br>BUILDING D, SUITE DM-900<br><sub>(Street)</sub><br>SAN FRANCISCO, CA 94129<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Eikon Therapeutics, Inc. [ EIKN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-02-04 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [X] 10% Owner<br>[ ] Officer (give title below)   [ ] Other (specify below)<br>_ _ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[ ] Form filed by One Reporting Person<br>[X] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 63691 | I | See footnote<sup>(1)</sup> |
| Common Stock | 3352 | I | See footnote<sup>(2)</sup> |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Series A Preferred Stock | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 1296629 | <sup>(3)</sup> | I | See footnote<sup>(1)</sup> |
| Series A Preferred Stock | <sup>(3)</sup> | <sup>(3)</sup> | Common Stock | 44249 | <sup>(3)</sup> | I | See footnote<sup>(2)</sup> |
| Series A-1 Preferred Stock | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 1403568 | <sup>(4)</sup> | I | See footnote<sup>(1)</sup> |
| Series A-1 Preferred Stock | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 47898 | <sup>(4)</sup> | I | See footnote<sup>(2)</sup> |
| Series C-1 Preferred Stock | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 110928 | <sup>(5)</sup> | I | See footnote<sup>(1)</sup> |
| Series C-1 Preferred Stock | <sup>(5)</sup> | <sup>(5)</sup> | Common Stock | 3785 | <sup>(5)</sup> | I | See footnote<sup>(2)</sup> |
| Series D Preferred Stock | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 688283 | <sup>(6)</sup> | I | See footnote<sup>(7)</sup> |
| Warrant | 2025-02-14 | 2030-02-14 | Common Stock | 573569 | $43.59 | I | See footnote<sup>(7)</sup> |

---

### Footnotes:

(1) The shares are directly held by The Column Group IV, LP ("TCG IV LP"). The Column Group IV GP, LP ("TCG IV GP LP") is the general partner of TCG IV LP and may be deemed to have voting and investment power with respect to shares directly held by TCG IV LP. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

(2) The shares are directly held by The Column Group IV-A, LP ("TCG IV-A LP"). TCG IV GP LP is the general partner of the TCG IV-A LP and may be deemed to have voting and investment power with respect to shares directly held by the Reporting Person. Peter Svennilson and Tim Kutzkey are the managing partners of TCG IV GP LP and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG IV-A LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

(3) The Series A Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Immediately prior to the closing of the Issuer's initial public offering ("IPO"), all shares of Series A Preferred Stock will be converted into shares of Common Stock of the Issuer.

(4) The Series A-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Immediately prior to the closing of the Issuer's IPO, all shares of Series A-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.

(5) The Series C-1 Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Immediately prior to the closing of the Issuer's IPO, all shares of Series C-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.

(6) The Series D Preferred Stock is convertible into Common Stock on a 1-for-7.4578 basis and has no expiration date. Immediately prior to the closing of the Issuer's IPO, all shares of Series C-1 Preferred Stock will be converted into shares of Common Stock of the Issuer.

(7) The securities are directly held by The Column Group Opportunity III, LP ("TCG Opportunity III LP"). The Column Group Opportunity III GP, LP ("TCG Opportunity III GP LP") is the general partner of TCG Opportunity III LP. TCG Opportunity III GP, LLC is the general partner of TCG Opportunity III GP LP and the ultimate general partner of TCG Opportunity III LP. Each of TCG Opportunity III GP LP and TCG Opportunity III GP, LLC may be deemed to have voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Peter Svennilson and Tim Kutzkey are the managing members of TCG Opportunity III GP, LLC and may each be deemed to share voting, investment and dispositive power with respect to securities directly held by TCG Opportunity III LP. Each of the Reporting Persons disclaims beneficial ownership of the securities noted herein, except to the extent of its or his pecuniary interest therein.

**Signature:** The Column Group IV, LP, by The Column Group IV GP, LP, its general partner, /s/ James Evangelista Attorney-in-Fact  
**Date:** 2026-02-04

**Signature:** The Column Group IV-A, LP, by The Column Group IV GP, LP, its general partner, /s/ James Evangelista Attorney-in-Fact  
**Date:** 2026-02-04

**Signature:** The Column Group IV GP, LP, /s/ James Evangelista Attorney-in-Fact  
**Date:** 2026-02-04

**Signature:** The Column Group Opportunity III, LP, by The Column Group Opportunity GP, LP its general partner, by TCG Opportunity III GP, LLC, its general partner, /s/ James Evangelista Attorney-in-Fact  
**Date:** 2026-02-04

**Signature:** The Column Group Opportunity GP, LP, by TCG Opportunity III GP, LLC, its general partner, /s/ James Evangelista Attorney-in-Fact  
**Date:** 2026-02-04

**Signature:** TCG Opportunity III GP, LLC, /s/ James Evangelista Attorney-in-Fact  
**Date:** 2026-02-04

**Signature:** /s/ James Evangelista, as attorney-in-fact for Tim Kutzkey  
**Date:** 2026-02-04

**Signature:** /s/ James Evangelista, as attorney-in-fact for Peter Svennilson  
**Date:** 2026-02-04

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**